ArticleMedComm2026
Hepatocellular Carcinoma Targeted Thermosensitive Cu
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cuproptosis is characterized by elevated intracellular copper concentrations that disrupt copper homeostasis and impair the tricarboxylic acid cycle, ultimately causing cell death. However, the lack of targeted intervention for intracellular copper may induce systemic side effects, hindering the application of cuproptosis in tumor therapy. Herein, we constructed a targeted copper ion delivery system (Cu-Lip-Gal(H)) based on galactose-modified thermosensitive liposomes, combined with local tumor hyperthermia targeted copper delivery into hepatocellular carcinoma (HCC) cells. Cu-Lip-Gal showed excellent physicochemical properties and 42°C thermosensitive release, with 64.67% ± 2.52% cumulative release within 0.5 h. The Cu-Lip-Gal(H) group reduced HepG2 and Huh7 cell viability to 24.48% ± 3.31% and 18.00% ± 3.18%, respectively; it exhibited 5.8-fold higher intracellular copper concentration in HepG2 cells and 5.2-fold higher in Huh7 cells. In nude mouse xenografts, Cu-Lip-Gal(H) achieved a tumor inhibition rate of 86.7% ± 1.9% without obvious histopathological changes in major organs but significantly increased necrotic cells in tumors along with the highest FDX1 expression levels observed in this study. These findings provide new insights into cuproptosis-based copper ion delivery systems for HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.